Catherine Ly

Dr. Catherine Ly

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2018 in Annual Review of Medicine
Verified
Journal Article
Closed access
JDJoseph Dayan
Joseph Dayan
CLCatherine Ly
Catherine Ly
RKRaghu P Kataru
Raghu P Kataru
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara
Lymphedema affects up to 1 in 6 patients who undergo treatment for a solid tumor in the United States. Its prevalence has increased as more effective oncologic therapies have improved patient survival, but there remains no definitive cure. Recent research has elucidated new details in the pathogenesis of the disease and has demonstrated that it is fundamentally an immunologic process that ultimately results in inflammation, fibroadipose deposition, impaired lymphangiogenesis, and dysfunctional lymphatic pumping. These findings have allowed for the development of novel medical and surgical therapies that may potentially alter the standard of care for a disease that has largely been treated by compression. This review seeks to provide an overview of the emerging therapies and how they can be utilized for effective management of lymphedema.

Verified
Journal Article
Open access
PDF file
CLCatherine Ly
Catherine Ly
RKRaghu P Kataru
Raghu P Kataru
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara
Lymphedema results from lymphatic insufficiency leading to a progressive inflammatory process that ultimately manifests as discomfort, recurrent infections, and, at times, secondary malignancy. Collectively, these morbidities contribute to an overall poor quality of life. Although there have been recent advances in microsurgical interventions, a conservative palliative approach remains the mainstay of treatment for this disabling disease. The absence of a cure is due to an incomplete understanding of the pathophysiological changes that result in lymphedema. A histological hallmark of lymphedema is inflammatory cell infiltration and recent studies with animal models and clinical biopsy specimens have suggested that this response plays a key role in the pathology of the disease. The purpose of this report is to provide an overview of the ongoing research in and the current understanding of the inflammatory manifestations of lymphedema.

17 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
GNGabriela D. García Nores
Gabriela D. García Nores
CLCatherine Ly
Catherine Ly
DCDaniel A. Cuzzone
Daniel A. Cuzzone
RKRaghu P Kataru
Raghu P Kataru
GHGeoffrey E. Hespe
Geoffrey E. Hespe
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara
T cell-mediated responses have been implicated in the development of fibrosis, impaired lymphangiogenesis, and lymphatic dysfunction in secondary lymphedema. Here we show that CD4+ T cells are necessary for lymphedema pathogenesis by utilizing adoptive transfer techniques in CD4 knockout mice that have undergone tail skin and lymphatic excision or popliteal lymph node dissection. We also demonstrate that T cell activation following lymphatic injury occurs in regional skin-draining lymph nodes after interaction with antigen-presenting cells such as dendritic cells. CD4+ T cell activation is associated with differentiation into a mixed T helper type 1 and 2 phenotype, as well as upregulation of adhesion molecules and chemokines that promote migration to the skin. Most importantly, we find that blocking T cell release from lymph nodes using a sphingosine-1-phosphate receptor modulator prevents lymphedema, suggesting that this approach may have clinical utility.

1 February 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
GNGabriela D. García Nores
Gabriela D. García Nores
CLCatherine Ly
Catherine Ly
ISIra L. Savetsky
Ira L. Savetsky
RKRaghu P Kataru
Raghu P Kataru
SGSwapna Ghanta
Swapna Ghanta
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara

1 April 2019 in Translational Research
Verified
Journal Article
Closed access
CLCatherine Ly
Catherine Ly
GNGabriela D. García Nores
Gabriela D. García Nores
RKRaghu P Kataru
Raghu P Kataru
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara

12 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JHJung-Ju Huang
Jung-Ju Huang
JGJason C. Gardenier
Jason C. Gardenier
GHGeoffrey E. Hespe
Geoffrey E. Hespe
GNGabriela D. García Nores
Gabriela D. García Nores
RKRaghu P Kataru
Raghu P Kataru
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara
Secondary lymphedema is a common complication of cancer treatment and recent studies have demonstrated that lymph node transplantation (LNT) can decrease swelling, as well as the incidence of infections. However, although these results are exciting, the mechanisms by which LNT improves these pathologic findings of lymphedema remain unknown. Using a transgenic mouse model of lymphedema, this study sought to analyze the effect of LNT on lymphatic regeneration and T cell-mediated immune responses. We used a mouse model in which the expression of the human diphtheria toxin receptor is driven by the FLT4 promoter to enable the local ablation of the lymphatic system through subdermal hindlimb diphtheria toxin injections. Popliteal lymph node dissection was subsequently performed after a two-week recovery period, followed by either orthotopic LNT or sham surgery after an additional two weeks. Hindlimb swelling, lymphatic vessel regeneration, immune cell trafficking, and T cell-mediated immune responses were analyzed 10 weeks later. LNT resulted in a marked decrease in hindlimb swelling, fibroadipose tissue deposition, and decreased accumulation of perilymphatic inflammatory cells, as compared to controls. In addition, LNT induced a marked lymphangiogenic response in both capillary and collecting lymphatic vessels. Interestingly, the resultant regenerated lymphatics were abnormal in appearance on lymphangiography, but LNT also led to a notable increase in dendritic cell trafficking from the periphery to the inguinal lymph nodes and improved adaptive immune responses. LNT decreases pathological changes of lymphedema and was shown to potently induce lymphangiogenesis. Lymphatic vessels induced by LNT were abnormal in appearance, but were functional and able to transport antigen-presenting cells. Animals treated with LNT have an increased ability to mount T cell-mediated immune responses when sensitized to antigens in the affected hindlimb.